ICYMI: Exa-cel for Beta Thalassemia, Sickle Cell Disease Accepted for Priority Review by Health Canada
On December 13, 1996, Health Canada issued a policy statement called Priority Review of Drug Submissions which: provided for the "fast-tracking" of eligible New Drug Submissions (NDS) and Supplemental New…